Drug Companies Update April 2009
Mergers, acquisitions & Joint Ventures
- Intranasal Therapeutics has changed its name to Ikano Therapeutics
- Access has acquired MacroChem
- Memory Pharmaceuticals has been acquired by Roche to become a wholly-owned subsidiary
- Sanofi-Aventis has completed its acquisition of Zentiva
- Winston Laboratories will henceforth be known as Winston Pharmaceuticals
New Companies
- Alios is developing novel antivirals based on three platform technologies.
- American Oriental Bioengineering is developing traditional Chinese medicines for pharmaceutical use.
- Calixa Therapeutics is focused on developing, acquiring and commercialising hospital-based anti-infectives.
- CDG Therapeutics is developing proprietary bacteria-derived peptides as cytotoxic agents for the treatment of cancer.
- Cebix is focused on chronic replacement therapy based on human proinsulin C-peptide for the treatment of Type I diabetic neuropathy as well as nephropathy and retinopathy.
- Cynvec was spun out of New York University and is developing anticancers using sindbis, its proprietary oncolytic viral vector.
- Gliknik is a biotech company developing therapeutics for cancer and autoimmune/inflammatory diseases.
- Jenrin is focused on peripherally-acting small molecules, modifying drugs to prevent transfer across the blood-brain barrier.
- Lentigen is biotech outfit utilising its proprietary lentiviral vector gene delivery technology.
- MBiotec is a German company founded to develop the lipopeptide compound MLP-2S for the treatment of cancer.
- NKT Therapeutics is developing therapies based on natural killer T-cells for a variety of indications.
- Paloma Pharmaceuticals has a range of small molecule therapeutics called Palomids for indications with a vascular factor.
- PDS Biotechnology is a start-up biopharmaceutical company using its Versamune technology to developing protein and peptide immunotherapies for the treatment of cancer and infectious disease.
- RetroVirox is dedicated to discovering new treatments for infectious disease.
- Selvita is a product provider to the Pharma industry with a preclinical research program developing in-house and in-licensed drug candidates with the aim of out-licensing or partnering for later-stage development.
- Signum Biosciences is developing signal transduction modulators for various disease areas.
- Sirona Biochem is an emerging biotech company with an initial focus on Type II diabetes and obesity.
- Terapio is developing a pipeline of systemic and topical therapies based on the naturally-occuring transport protein RLIP-76.
- Thrasos Therapeutics is developing small molecule therapeutics which target key receptors of the bone morphogenetic protein family for the treatment and prevention of sever organ failure.
- TI Pharma is a collaborative structure consisting of academic and industrial research teams.
- Thymon is a New Jersey-based company developing an anti-HIV-1 vaccine.
- TRF Pharma is developing P-selectin inhibitors.
- Ulysses Pharmaceuticals is developing novel antibiotics for resistant bacterial infections.
- VaxOnco is developing cancer vaccines.
